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The regional mouse brain distribution of a new carbon-11 labeled 
derivative of vesamicol, [llC]-5(N-methylamino)benzovesamicol 
(IllCIMABV) is reported. Radiotracer concentrations in uiuo are in the 
rank order of striatum>cortex>hippocampus>hypothalamus> 
cerebellum, consistent with reported distributions of other presynaptic 
cholinergic neuronal markers. In time course studies, 
striatum/cerebellum and cortex/cerebellum ratios for (-)-[llClMABV 
continue to increase to values of 13 and 5, respectively, 75 min after i.v. 
injection of [llC]MABV. The specific binding in striatum and cortex is 
lowered by pretreatment with (+vesamicol, and shows stereoselectivity 
with lower uptake and lower ratios for the (+)-enantiomer. (->- 
[llC]MABV is proposed as a positron-emitting radioligand for the in uiuo 
study of presynaptic cholinergic neurons. 
Alzheimer’s disease is characterized by degeneration of the cholinergic 
neurotransmitter system. The unique biochemical characteristics of the cholinergic 
neuron, such as high affinity choline uptake (HAChU), choline acetyltransferase 
(ChAT), and vesicular storage of acetylcholine have been thoroughly studied in vitro 
using radiotracer or immunochermstry techniques. Declines in ChAT and HAChU, as 
well as in acetylcholmesterase, are now widely recognized features of the 
neurochemical pathology in Alzheimer’s disease (1,2,3). Radiotracers which mark 
specific presynaptic biochemical processes of cholinergic neurons might be useful for 
assessment of changes in function or number of such terminals rn uiuo using positron 
emission tomography (PET). Vesamicol (2-(4-phenylplperidino)cyclohexanol: 
AH5183) binds to a specific site on presynaptic acetylcholine storage vesicles where it 
acts as a stereoselective, non-competitive, allosteric inhibitor of acetylcholine uptake 
into the vesicle (4,5,6). We have prepared a high specific activity, carbon-11 (p+, ty2 = 
20.4 min> labeled derivative of vesamicol, (N-([llClmethyl)-aminobenzovesamicol 
([llC]MABV), and report here preliminary in wuo biodistribution results in mouse 
brain. 
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Fig. 1. N-([lWlMethyl)-aminobenzovesamicol WCIMABV). 
Chemicala 
(-) -Vesamicol was obtained from Research Biochemicals, Inc. (Natick, MA). 
5Aminobenzovesamicol (ABV) was prepared by literature methods (5) and resolved 
by chiral HPLC (Chiracel OD column, 4.6 x 250 mm, hexane:isopropanol). Authentic 
N-methylaminobenzovesamicol was prepared from ABV by reaction of the aniline 
with benzylchloroformate and reduction of the intermediate with lithium aluminum 
hydride. The product fully characterized (1H and 13C NMR, mass spec, C,H,N 
analysis). 
CllClMABV was prepared by N-methylation of aminobenzovesamicol. 
111ClMethyl iodide, prepared by standard methods (71, was bubbled into a solution of 
ARV (1 mg, as methanesulfonate salt) in 0.250 ml of DMF at -25 OC. The solution 
was heated to 125 OC for 15 minutes, cooled, and injected onto the HPLC. 
Purification was done using a semi-preparative Cl8 column (Maxsil Cl& 5 micron, 
7.6 x 300 mm) eluted with CH&N/Cl&OWll mM NaH2PO4 (3 / 1/ 2.25, V/V/V), pH = 
7, at 1 ml/min. Retention times of MABV and ABV were 17.5 and 24 min, 
respectively. Isolated [1K!]MABV was prepared for injection by evaporation of the 
HPLC solvent and dissolving the product in sterile saline. Yields were 15-20% 
(corrected for decay). Radiochemical and chemical purity, and specific activity, were 
obtained from a separate injection of formulated product on an analytical HPLC 
column : Maxsil Cl& 4.6 x 250 mm; solvent system as above: Rt MABV = 15 min, Rt 
ABV = 10 min. Radiochemical purity was further checked using thin layer 
chromatography (silica gel, 40/60 hexane/ethylacetate, Rf = 0.4). Full details of the 
synthesis of the cold and radioactively labeled compounds will be presented elsewhere 
(Jung et al in preparation). 
Retional Brain Di&&utions 
Regional brain distribution studies were performed in female CD-l mice, 20-25 
g (Charles River). For each data point 4-5 animals were used. Animals were 
anesthetized with diethyl ether and [lW]MABV (50-75 &i, 50-100 ng) injected via 
the tail vein. The animals were allowed to recover, then sacrificed by decapitation at 
designated times. A blood sample was obtained, and the brain rapidly removed and 
dissected into samples of striatum, occipital cortex, hippocampus, hypothalamus and 
cerebellum (8). Tissue samples were counted for carbon-11 and then weighed. Data 
was calculated as % injected dose per gram (%ID/g) of tissue, and % ID/brain. 
Pharmacological blocking studies were done by i.v. administration of 
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(Gvesamicol (300 pg/kg, 100 ~1 volume bolus injection) 10 minutes prior to 
radiotracer injection, followed by sacrifice and dissection according to the above 
protocol. 
Data were analyzed for statistical significance using an unpaired Student’s t- 
test. 
Metabolite i 
Two animals were injected with approximately 100 PCi each of (-)-[llC]MABV. 
After 45 minutes, the animals were killed and the brains removed and dissected. 
Samples of the striatum were pooled and homogenized in a small volume (0.1 ml) of 
100% ethanol. The ethanol extract was analyzed by thin layer chromatography (silica 
gel, 50/50 hexane/ethylacetate, Rf = 0.50) and the distribution of radioactivity on the 
plate determined using a Berthold Automatic TLC-Linear Analyzer. In control 
experiments, 1 microcurie of authentic [N]MABV was added to separate samples of 
striatal tissue from mouse brain, and the homogenization, extraction and 
chromatography steps performed as described above. 
The time course of regional distribution of (-)-[llC]MABV is shown in Figure 2. 
With the exception of the striatum, tissue radioactivity levels were highest at the 
early time point and steadily decreased. Striatal radioactivity levels were not 
significantly different at early and late time points. 
The regional brain distributions of carbon-11 radioactivity 45 minutes after 
injection of the (+), (-1 and racemic forms of [llC]MABV are compared in Table 1. The 
highest radioactivity concentration in all cases was in the striatum and lowest in the 
cerebellum. The regional brain distribution of (+)-MABV at 45 min shows lower 
retention of radiotracer in all tissues, and significantly lower STR/CER and STRKTX 
ratios for this isomer. At 75 minutes the tissue levels continue to decrease, giving 
lower STWCER and STRKTX ratios (data not shown). Regional radioactivity 
distribution for @)-PlClMABV after pretreatment with 300 &kg (-)-vesamicol is also 
shown in Table 1. Radiotracer accumulation was most reduced in the striatum 
(-300/o>, but also lower in the cortex, hippocampus and hypothalamus (20-30% 
reductions). Radiotracer levels in cerebellum and blood remained unaffected by 
vesamicol pretreatment. 
Analysis of extracts of radioactivity from striatal tissues gave a 
radiochromatogram identical to that obtained in control experiments with authentic 
PXIMABV, suggesting the presence of only unchanged [llC]MABV. 
Radiotracers specific for binding sites on presynaptic neurons have the 
potential to provide information on the in uiuo integrity of specific neurotransmitter 
systems. Alone, such radiotracers might provide valuable information on the regional 
concentrations of neurons present in normal and diseased brain. Used in conjunction 
with measures of neurotransmitter synthesis rates, or of postsynaptic receptor 
densities, they may offer a method for more complete understanding of the normal 
function of synaptic processes and their possible malfunction in disease states. We 
have previously prepared such presynaptic markers for the dopaminergic (91, 
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Time course of [fX!]hNEW uptake and retention in specific regons of 
mouse brain. Values shown are means f SD for four to six animals per 
time point. STR = striatum, C’I’X = cortex, CER = cerebellum, HIPPO = 
hippocampus, HYPO = hypothalamus. 
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TABLE I 
(+MABv (-mfABv PwAl3v WMABV + 
300 mg/kg 
(+esamicol 
Striatum 1.23 +.lO* 8.1 k.44 6.41 * .21 3.91 + .49* 
Cortex 0.91*.06* 3.99 +.22 3.38 f .14 2.33 + .26** 
Hippocampus 0.93 *.04* 3.58 i.19 3.23 + .65 2.23 f .26** 
Hypothalamus 0.88 2.04* 2.23 +.ll 2.22 2.09 1.80 f .24 
Cerebellum 0.73 +.07* 1.05 i.25 1.09 k.04 1.05 f .14 
Blood 0.41+.02* 0.54 k.03 0.65 + .02 0.61 k.04 
STIUCER 1.75 &.23* 7.75 .18 5.81 f .28 3.72 *.35** 
CTXKER 1.25 +.15* 3.81 .22 3.14 f .51 2.23 + .27** 
sTRCTx 1.36 &.2* 2.02 .08 1.91 f .24 1.67 i.08 
%dose/brain 1.49 +.21 1.46 f .16 1.46 +.14 0.97 + .09** 
+ Data given as mean f SD, 
with 3 to 5 animals per data point 
*p < 0.05 compared to 45 min (-)MABV 
**p < 0.05 compared to 45 min (*)MABV 
Regional Brain Distribution of (-), (+) and (Q[llClMABV in CD-1 
Mouse Brain at 45 minutes after i.v. Injection. 
noradrenergic (lo), and GABA-ergic (11) systems, and the present work is an 
extension of this effort to the choline&c system. Development of a presynaptic 
cholinergic marker for PET studies is similar to our recent efforts to prepare 
radioiodinated vesamicol derivatives for single photon emission computed 
tomography (SPECT) studies (121, and complements efforts in our laboratories and 
others to study postsynaptic muscarinic acetylcholinergic receptors using gamma- 
emitting radiotracers (13-19 >. 
Vesamicol binds in a high affinity, stereoselective fashion to a specific site on 
vesicles of cholinergic neurons. A large number of derivatives of vesamicol have been 
recently synthesized and several of these compounds show equal or better affinities 
for the vesamicol binding site (5). Of particular note are the derivatives of 
benzovesamicol (trans - 2-hydroxy-3-(4-phenylpiperidino)tetraIin, IC5o = 50 nM), in 
which considerable steric tolerance in the 5-position was evident in the structure- 
activity study. Substituents ranging from small (amino) to quite large 
(biotinylglycineglycine) are well tolerated (5). Vesamicol offers few good options for 
radiolabeling with carbon-11 or fluorine-18, but 5aminobenzovesamicol (IC5o = 100 
nM) offers numerous possibilities for labeling with fluorine-18 (p+, tu2 = 110 min) or 
carbon-11. N-[llClalkyl, N-[lsF]fluoroalkyl, N-[UZlacyl and N[lsFlfluoroacyl 
derivatives of benzovesamicol, as well as radioiodinated derivatives (21), are all of 
considerable promise. We chose, due to the simplicity of the labeling reaction and the 
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ready availability of high specific activity (GO00 Ci/mmol) [llC]methyl iodide, to 
initially prepare the N-methyl derivative, 5-[11Clmethyl-aminobenzovesamicol 
([XXUBV). This radiotracer was prepared by simple methylation of the primary 
aniline and the desired [llC]MABV was isolated in high radiochemical purity (>97%) 
and high specific activity (500-700 CiAnmol at end-of-synthesis). 
We have examined the time course of regional brain distribution of pure 
(-)-PKJIMABV over 75 min, or nearly 4 half-lives of carbon-11 (Figure 2). Initial 
uptake of radiotracer was high in all regions of the brain, followed by rapid washout 
from cerebellum, slower washout from cortex, and little efBux from striatum. The 
STRXER, CTX/CER and STIUCTX ratios continued to increase throughout the study 
to maximum values of 13 , 5 and 2.6, respectively. At 75 min the relative tissue 
concentrations for (->-[llC]MABV are in the order of striatum > cortex >hippocampus 
> hypothalamus > cerebellum, and are similar to in urtro results from 
autoradiography with [3Hlvesamicol(4,6), membrane binding studies with the choline 
uptake inhibitor [XIjhemicholinium-3 (20,21)), and cholineacetyltransferase activities 
(22,23,24). Direct comparisons of our data with previous studies must be made 
carefully, due to possible differences in species (rat vs. mouse vs. human), tissues 
chosen (cortical regions), finer spatial resolution in the autoradiographic studies, and 
in uztro vs. in uiuo assay techniques. However, simply using the relative tissue 
concentrations of [llC]MABV as an estimate of specific binding with no correction for 
underlying non-specific binding and no assumptions regarding specific binding sites 
in the cerebellum, gives a dynamic range (max/min or STRKER of 13) which is 
certainly less than that obtained for ChAT in rat brain (STIUCER of >25) but similar 
to the STRKER ratios found with the other presynaptic cholinergic markers (20-24). 
The intermediate concentration of 111ClMABV in the cortex, expressed as a STWCTX 
ratio of 2.6, is furthermore consistent with the range of STRKTX ratios (1.8 to 4.7) 
found with [3H]vesamicol, [3H]hemicholinium-3, and ChAT activities (22-26). At 75 
minutes the concentration of [1KXKABV in cerebellum, hippocampus, occipital cortex 
and striatum is linearly correlated (r 2 = 0.97) with ChAT levels in these regions of rat 
brain (ChAT data from Fig. 2,reference 6) . Finally, the regional brain distribution 
achieved here with [llC]MABV is very similar to the results recently reported for the 
radioiodinated derivative, 5-[125Ijiodobenzovesamicol(12). 
The STR/C!ER at 75 min for (-)+lClMABV is also quite similar to that 
obtained in CD-1 mice with the muscarinic receptor antagonist 111Cltropanyl 
benzilate ([llC]TRB) (13). Consistent with the in urtro results using [3Hlvesamicol 
(6), however, we found a poorer correlation (r-2 = 0.75) of in utuo PlClMABV 
concentrations with [SHIQNB binding (25) in the four brain regions studied here. The 
maximum target/non-target ratio obtained with [llC]MABV is significantly better 
than we and others have obtained with radioligands for the neuronal monoamine 
reuptake systems (12,13,26,27,28,29). 
In in uztro binding assays vesamicol shows stereoselectivity for the vesicular 
binding site [(-)-(R,R)-vesamicol being the more active], and thus the use of the less 
active isomer might afford an in uiuo measure of nonspecific binding. We have 
examined the regional binding of the (-)-, &:)-, and (+)- isomers of [llC]MABV (Table 
1). The retention of radioactivity in the brain tissues shows the stereoselectivity 
expected for derivatives of vesamicol, with the tissue concentrations and selectivity 
(as STRKER or STRKTX ratios) greatest for the (-)-enantiomer, intermediate for the 
racemic mixture, and lowest for the (+)-enantiomer The statistically lower 
cerebellum levels for the (+)-isomer may reflect the effect of the lower blood 
concentration. There was, however, some selective retention of the radioactivity in 
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target tissues after administration of (+)MABV (STRKER = 1.75). It is not clear if 
this was due to: (a) some affinity of this “wrong” isomer for the vesamicol binding 
site, or (b) binding of (+I-MABV to a separate unknown site. It should be noted that 
vesamicol shows stereoselectivity but it does bet show stereospecificity: the K&o 
value for the (+)-vesamicol is 25fold greater than the (-1 isomer but still less than 
millimolar, and (+)-vesamicol has been shown in vitro to displace (-1 vesamicol from 
vesicle membranes (5). Thus, the brain retention of (+I-[11ClMABV in this 
experiment may not solely represent non-specific binding of radiotracer. 
Pharmacological specificity of zn uiuo radiotracer binding, and extent of non- 
specific binding or binding to nontarget receptors, can usually be determined through 
the use of appropriate blocking studies. Vesamicol and its derivatives pose unusual 
problems in this respect, due to the reported (5) high toxicity of this class of 
compounds (vesamicol LD50 = 3 mg/kg; benzovesamicol LDso = 0.3mg/kg; toxicity of 
MABV is unknown). There are no other known high affinity antagonists for this 
binding site, and pharmacological agents which alter cholinergic function (receptor 
agonists or antagonist) should not affect this allosteric binding site. As the toxicity of 
(+vesamicol is known (5) it was chosen for these studies, and the blocking dose 
utilized (300 @kg) did not result in severe pharmacological actions or death. At 600 
to 900 &kg, however, the dose was 5060% fatal. At the lower 300 &g dose of W- 
vesamicol, the binding of O- [WIMABV shows a consistent decrease of radiotracer 
retention in target areas; indicators of specific binding, calculated as either STRK!ER 
ratios or (%ID STR - %ID CER) showed a 3040% decrease in the treated animals. 
Concentrations of radioactivity in the nontarget tissue (cerebellum) or blood remained 
unchanged. This is clearly not a full pharmacological blockade of selective radiotracer 
accumulation and retention, but a complete dose-response curve was not possible due 
to toxicity limitations. Although we cannot be sure that higher doses would block 
more binding sites, in those relatively few animals which survived treatment at 600 
pg/kg and were then studied with [W!lMABV or 5-[12sIliodobenzovesamicol (121, 
reductions in specific binding of 50-65% were observed. It should be noted that the 
blocking doses used in this study were considerably less than doses we have 
commonly employed (2-20 mg/kg) for complete in uzuo blockade of neurotransmitter 
receptor or uptake system binding sites (9,lO). 
An important concern in use of zn uiuo radiotracers is the generation and tissue 
distribution of radiolabeled metabolites. In preliminary studies we have homogenized 
brain tissue of mice 45 minutes after injection of (-)-[lW]MABV and examined the 
extracts for presence of metabolites. This study showed no metabolites of [W]MA.BV 
in brain tissue. This finding was consistent with the results of Jung et al (12) with 
W5Iliodobenzovesamicol. 
In this work we have evaluated the first positron-emitter labeled radiotracer 
specific for the vesicles of cholinergic neurons. These in uiuo results answer 
important initial questions in the development of a new radioligand: [WIMABV 
shows regional, stereoselective retention in brain regions corresponding to known 
high concentrations of ChAT, HAChU, and AChE; the brain extraction and retention 
of radiotracer are sufficiently high to permit PET studies; and there are no 
radiolabeled metabolites in the target tissue. These results are encouraging and 
support the concept that (-WCIMABV and PET can be successfully used to image 
the distribution of vesamicol binding sites, and thus presynaptic cholinergic neurons. 
The ability of this radiotracer to provide kinetic data suitable for pharmacokinetic 
modeling and determination of quantitative parameters (KD 
1962 Presynaptic Marker of Cholinergic Neurons Vol. 47, No. 21, 1990 
accomplished using primates and are currently underway; using PET and monkeys 
we have imaged the striatum and cortex of the primate brain (K.A. Frey, M.R. 
Kilbourn et al, unpublished). 
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